These drugs include pioglitazone, which improves hepatic steatosis, necroinflammation, and fibrosis; glucagon-like peptide 1 (GLP-1) agonists that improve hepatic steatosis and necroinflammation; and sodium-glucose cotransporter 2 (SGLT2) inhibitors that improve hepatic steatosis, necroinflammation, and liver enzymes. Here, SLC5A2 is linked to fatty liver disease.